Idiopathic recurrent stupor

Idiopathic recurrent stupor (IRS), also known as endozepine stupor, is an extremely rare neurological condition characterized by recurrent episodes of stupor or coma that occur without any identifiable structural, metabolic, toxic, or psychiatric cause. During episodes, affected individuals experience a profound reduction in consciousness, ranging from deep drowsiness to complete unresponsiveness, that can last from hours to several days. Between episodes, patients typically return to a normal level of consciousness and neurological function. The condition primarily affects the central nervous system. During stuporous episodes, electroencephalography (EEG) characteristically shows diffuse fast beta activity, similar to patterns seen with benzodiazepine use. Early reports suggested that elevated levels of endozepine-4, an endogenous benzodiazepine-like substance, could be detected in the plasma and cerebrospinal fluid of affected patients during episodes. Notably, administration of flumazenil, a benzodiazepine receptor antagonist, was reported to rapidly reverse the stuporous state in some cases, providing both a diagnostic clue and a potential treatment approach. However, the existence of idiopathic recurrent stupor as a distinct clinical entity has been debated in the medical literature. Some cases initially attributed to IRS were later found to be associated with surreptitious benzodiazepine use, raising questions about the validity of the diagnosis. The condition remains controversial, and clinicians must rigorously exclude exogenous benzodiazepine exposure and other causes of recurrent altered consciousness before considering this diagnosis. There is no established long-term treatment, and management is largely supportive, with flumazenil used acutely during episodes in reported cases.

Common questions about Idiopathic recurrent stupor